


Supplementary data:

Methods:

Infant stool samples were collected by the mothers to a sterile stool collection tube and were frozen immediately. Samples were kept in -80 until analysis. After thaw, infant stool samples were diluted 1:5 in stool preservative buffer (PBS, 0.05m EDTA, 1X proteinase inhibitor). Samples were later diluted 1:10 in sample dilutant buffer (Ray-Biotech, GA, USA, IEQ-CoVS1RBD-IgG-1 and IEQ-CoVS1RBD-IgA-1), filtered through a 0.2µm filter, and assayed by ELISA using the same protocol above used for milk.

Results:

Anti SARS-CoV-2 RBD IgG antibodies were detected in infant stool samples: We further examined whether the anti SARS-CoV-2 IgG antibodies that were consumed by breastfeeding infants could survive the acidic conditions and enzymatic reactions in the intestinal tract. To address this question, we collected stool samples from one infant at 4 time points, pre-vaccine, on the day after the 2nd dose, and 4 and 8 weeks after the 2nd dose. We also collected paired samples of maternal milk at the same time points and measured these for the presence of anti SARS-CoV-2 IgG and IgA antibodies using ELISA. We were able to detect anti-SARS-CoV-2 IgG antibodies in post-vaccine samples collected 4 weeks and 8 weeks following the 2nd dose. These antibodies were not present in the pre-vaccine stool samples or in the sample collected one day after the 2nd dose (when milk IgG levels were still low) (**Figure S1**).



S

Figure S1: Detection of anti-SARS-CoV2 RBD IgG in milk and stool samples. Milk and stool samples were collected from one mother-baby dyad at various time points (X axis) and were assayed by ELISA. Note: milk samples are diluted in 1:2 ratio in assay samples buffer, and stool samples are diluted 1:5 in stool preservative buffer and 1:10 in assay samples buffer.